DODenise M. O'SUllivan

Denise M. O'SUllivan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denise M. O'SUllivan has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methods to Improve Confidence in the Accuracy of Molecular Testing for Multidrug-Resistant Tuberculosis

    by Denise M O’SUllivan, Gerwyn M Jones, Manca Zolnir-Dovc, Richard Phillips, Rejoice Arthur, Bariki Mtafya, Daniel Adon Mapamba, Daniela Maria Cirillo, Ewa Augustynowicz-Kopeć, Mei Mei Ho, et al.

    Background: Diagnosis of tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) is increasingly performed using molecular tools that detect Mycobacterium tuberculosis DNA. To ensure accurate and reliable results from the molecular tests, appropriate quality assessment is required. This involves implementing reference measurement procedures (RMPs) to characterize material standards that are representative of the clinical specimen. These material standards should address drug resistance and mixtures of drug-resistant and -susceptible bacteria. However, currently these RMPs and materials standards do not exist, which can hamper the accuracy and precision of routine clinical testing. To address this, we applied digital PCR (dPCR) as a RMP to MDR-TB material standards. Methods: Four standards were prepared and characterized using dPCR to quantify drug-resistant and -susceptible genotypes. We investigated the performance of existing molecular tests via an interlaboratory study including 9 laboratories from Africa and Europe, assessing 3 methods for MDR-TB detection and 2 methods for TB-only detection. Results: All tests correctly identified M. tuberculosis, and 2 out of 3 tests identified the associated drug resistance (one test failed to identify drug resistance in one of the materials). Generally, discrepancies occurred with the more challenging samples bearing lower concentrations and mixed genotypes. Conclusions: The approaches used in this study will enhance the quality assessment of MDR-TB and can be applied to afford test manufacturers and clinical laboratories more accurate results to guide test development, selection, and regulation. Such an approach can improve confidence in MDR-TB testing, enabling physicians to guide treatment, potentially leading to better patient outcomes.


  • Open Access

    An assessment of molecular diagnosis of tuberculosis and multi-drug resistant tuberculosis testing and quality assessment: findings of an international survey

    by Jim F. Huggett, Daniel Evans, Denise M. O’sUllivan, Katell Peoc’h, Helia Bakhshi-Nejad, Amanda Winter, Alimuddin Zumla, Timothy D. McHugh, Mikashmi Kohli, Anita Suresh, et al.

    Molecular ‘ in vitro diagnostic’ (IVD) tests are established for the diagnosis of tuberculosis (TB) and multi-drug resistant TB (MDR-TB). What is less clear is how the use of TB or MDR-TB molecular IVD results differ across regions, whether corroborative tests are conducted and what external quality assessment (EQA) infrastructure exists to underpin test confidence. This study investigated the current international status of molecular TB IVDs methods, application and quality assessment. An online survey was distributed by the IFCC’s Committee for molecular diagnostics to TB diagnostic laboratories worldwide. 118 laboratories from 41 nations indicated a range of IVDs were used. ∼75 % participated in EQA programs and 32 % reported this used the WHO International Standard. ∼65 % also delivered MDR-TB results the majority of which were used to change therapy; 1/6 of these do so without EQA evaluation of the MDR-TB result. The study demonstrates a range of IVD solutions in use for TB diagnosis along with a high uptake of EQA in support of this global uptake of this test modality. However, we also reveal gaps in quality assurance for MDR-TB testing with 10 % of the laboratories using resistant results alone without participating MDR-TB EQA. This suggest additional work is required to build on established use of EQA to better support MDR-TB testing and better ensure confident when results are used to guide antibiotic use. Addressing these gaps will ensure the accuracy of future MDR-TB results, which is critical for effective disease management and help combat TB on a global scale.


  • Open Access

    The Application of Digital PCR as a Reference Measurement Procedure to Support the Accuracy of Quality Assurance for Infectious Disease Molecular Diagnostic Testing

    by Samreen Falak, Denise M O’sUllivan, Megan H Cleveland, Simon Cowen, Eloise J Busby, Alison S Devonshire, Esmeralda Valiente, Gerwyn M Jones, Martin Kammel, Mojca Milavec, et al.

    Background: Nucleic acid amplification tests (NAATs) assist in the diagnosis of numerous infectious diseases. They are typically sensitive and specific and can be quickly developed and adapted. Far more challenging is the development of standards to ensure NAATs are performing within specification; reference materials take time to develop and suitable reference measurement procedures (RMPs) have not been available. This study investigated digital PCR (dPCR) RMP delivery of traceability for NAAT external quality assessment (EQA). Methods: Three National Metrology Institutes (NMIs) applied reverse transcription (RT)-dPCR as a candidate RMP to estimate the RNA quantity in 32 independent severe acute respiratory syndrome coronavirus 2 materials. The results were combined to value assign the respective materials: 21 materials were used in 6 rounds of EQA over 17 months for 61 laboratories for COVID-19 testing results compared with reference values. Results: The agreement between the 3 NMIs showed <2-fold difference between laboratories. EQA laboratory reverse transcription quantitative PCR (RT-qPCR) values estimation of viral RNA quantity showed good median agreement with RT-dPCR reference value; however, RT-qPCR differences were generally between 10- and 50-fold between laboratories. Conclusion: This work demonstrates how RT-dPCR can provide reference values for whole virus materials for NAAT quality assurance. RT-dPCR values guided EQA control material selection and provided EQA participants with traceability to RNA copy number delivered through the RMP. This approach can be used to support routine reference material use as well as to standardize quality assurance for NAATs where established reference materials are not available, such as in disease outbreaks.


  • Comparison of SARS-CoV-2 N gene real-time RT-PCR targets and commercially available mastermixes

    by Julianne R. Brown, Denise M. O’sUllivan, Divya Shah, Laura Atkinson, Rui P.A. Pereira, Alexandra S. Whale, Eloise J. Busby, Jim F. Huggett, Kathryn Harris


  • Open Access

    Discordant bioinformatic predictions of antimicrobial resistance from whole-genome sequencing data of bacterial isolates: an inter-laboratory study

    by Ronan M. Doyle, Denise M. O'SUllivan, Sean D. Aller, Sebastian Bruchmann, Taane Clark, Andreu Coello Pelegrin, Martin Cormican, Ernest Diez Benavente, Matthew J. Ellington, Elaine McGrath, et al.

    Antimicrobial resistance (AMR) poses a threat to public health. Clinical microbiology laboratories typically rely on culturing bacteria for antimicrobial-susceptibility testing (AST). As the implementation costs and technical barriers fall, whole-genome sequencing (WGS) has emerged as a ‘one-stop’ test for epidemiological and predictive AST results. Few published comparisons exist for the myriad analytical pipelines used for predicting AMR. To address this, we performed an inter-laboratory study providing sets of participating researchers with identical short-read WGS data from clinical isolates, allowing us to assess the reproducibility of the bioinformatic prediction of AMR between participants, and identify problem cases and factors that lead to discordant results. We produced ten WGS datasets of varying quality from cultured carbapenem-resistant organisms obtained from clinical samples sequenced on either an Illumina NextSeq or HiSeq instrument. Nine participating teams (‘participants’) were provided these sequence data without any other contextual information. Each participant used their choice of pipeline to determine the species, the presence of resistance-associated genes, and to predict susceptibility or resistance to amikacin, gentamicin, ciprofloxacin and cefotaxime. We found participants predicted different numbers of AMR-associated genes and different gene variants from the same clinical samples. The quality of the sequence data, choice of bioinformatic pipeline and interpretation of the results all contributed to discordance between participants. Although much of the inaccurate gene variant annotation did not affect genotypic resistance predictions, we observed low specificity when compared to phenotypic AST results, but this improved in samples with higher read depths. Had the results been used to predict AST and guide treatment, a different antibiotic would have been recommended for each isolate by at least one participant. These challenges, at the final analytical stage of using WGS to predict AMR, suggest the need for refinements when using this technology in clinical settings. Comprehensive public resistance sequence databases, full recommendations on sequence data quality and standardization in the comparisons between genotype and resistance phenotypes will all play a fundamental role in the successful implementation of AST prediction using WGS in clinical microbiology laboratories.


  • Open Access

    Development and optimization of a gas chromatography/mass spectrometry method for the analysis of thermochemolytic degradation products of phthiocerol dimycocerosate waxes found in Mycobacterium tuberculosis

    by Simona C. Nicoara, David E. Minnikin, Oona C. Y. Lee, Denise M. O'SUllivan, Ruth McNerney, Collin T. Pillinger, Ian P. Wright, Geraint H. Morgan

    RATIONALE: The phthiocerol dimycocerosates (PDIMs) are certain stable and hydrophobic waxes found in the cell membrane of Mycobacterium tuberculosis , bacteria that cause an infectious disease of growing concern worldwide. Previous studies report the analysis of derivatives of the hydrolysed PDIMs from biological samples, following complex extraction and offline derivatization of PDIMs biomarkers, prior to their analysis by gas chromatography/mass spectrometry (GC/MS). METHODS: We developed and optimized a GC/MS method based on selected ion monitoring (SIM) to detect the derivatives produced via the thermally assisted hydrolysis and methylation (THM) of the PDIMs from the cell membrane of M. tuberculosis . The extraction of PDIMs from culture is simple, and their thermochemolysis is carried out automatically online, thus avoiding the time‐consuming derivatization steps of hydrolysis and esterification, usually performed offline. RESULTS: For standard PDIMs in petroleum ether, our optimized method gave an excellent linearity (R 2 = 0.99) at concentrations between 0.172 and 27.5 ng/mL, a good precision (RSD = 11.42 %), and a limit of detection (LOD) of 100 pg/mL. For the PDIMs extracted from dilutions of M. tuberculosis culture, the method gave good linearity (R 2 = 0.9685) and an estimated LOD of 400 CFU/mL (CFU = colony forming units) in sterile distilled water. CONCLUSIONS: A GC/MS(SIM) method is presented for the rapid and quantitative detection of M. tuberculosis , based on the online thermochemolysis of lipidic biomarkers extracted from the bacterial culture. The method has the potential to be applied in human and veterinary clinical laboratories for the rapid diagnosis of tuberculosis in infected biological samples. © 2013 The Authors. Rapid Communications in Mass Spectrometry published by John Wiley & Sons, Ltd.